Glioblastoma multiforme natural history: Difference between revisions
Jump to navigation
Jump to search
| Line 22: | Line 22: | ||
==Prognosis== | ==Prognosis== | ||
*Depending on the extent of glioblastoma at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor. | *Depending on the extent of glioblastoma at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor, and the 5-year mortality rate of patients with glioblastoma is approximately 10%. | ||
*Negative prognostic factors include:<ref name=ddd>Prognosis of glioblastoma multiforme. Dr Dylan Kurda and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/glioblastoma</ref> | *Negative prognostic factors include:<ref name=ddd>Prognosis of glioblastoma multiforme. Dr Dylan Kurda and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/glioblastoma</ref> | ||
**Degree of necrosis | **Degree of [[necrosis]] | ||
**Degree of enhancement | **Degree of enhancement | ||
**Deep location (e.g. thalamus) | **Deep location (e.g. [[thalamus]]) | ||
*Median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. | *Median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. | ||
*With standard treatment ([[radiotherapy]], [[chemotherapy]], and [[surgery]]), the median survival is approximately 14 months | *With standard treatment ([[radiotherapy]], [[chemotherapy]], and [[surgery]]), the median survival is approximately 14 months.<ref>{{cite journal | author = Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R | title = Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. | journal = N Engl J Med | volume = 352 | issue = 10 | pages = 987-96 | year = 2005 | id = PMID 15758009}}</ref> | ||
==References== | ==References== | ||
Revision as of 20:10, 14 September 2015
|
Glioblastoma multiforme Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glioblastoma multiforme natural history On the Web |
|
American Roentgen Ray Society Images of Glioblastoma multiforme natural history |
|
Risk calculators and risk factors for Glioblastoma multiforme natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Natural History
Complications
Common complications of glioblastoma include:[1]
- Herniation (axial, transtentorial, subfalcine, tonsillar)
- Systemic illness
- Dysphagia
- Aphasia
- Brainstem invasion by tumor
- Neutron-induced cerebral injury
- Weakness
- Fatigue
- Numbness
- Surgical complications (cerebral hemorrhage, edema)
- Coma
Prognosis
- Depending on the extent of glioblastoma at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor, and the 5-year mortality rate of patients with glioblastoma is approximately 10%.
- Negative prognostic factors include:[2]
- Median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk.
- With standard treatment (radiotherapy, chemotherapy, and surgery), the median survival is approximately 14 months.[3]
References
- ↑ Silbergeld DL, Rostomily RC, Alvord EC (1991). "The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults". J Neurooncol. 10 (2): 179–85. PMID 1654403.
- ↑ Prognosis of glioblastoma multiforme. Dr Dylan Kurda and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/glioblastoma
- ↑ Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R (2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N Engl J Med. 352 (10): 987–96. PMID 15758009.